BARRY S. TAUS specializes in litigating complex antitrust class actions. Mr. Taus currently represents plaintiffs and class members in various antitrust class actions, including numerous actions brought on behalf of direct purchasers of pharmaceutical products. These actions allege that brand name pharmaceutical companies committed various acts to wrongfully prevent or delay competition from less expensive generic versions of brand name drugs. , In re Wellbutrin XL Antitrust Litigation, In re Effexor XR Antitrust Litigation,and In re Niaspan Antitrust Litigation,
Mr. Taus also represents purchasers or renters of other products who have overpaid because of antitrust violations by monopolists, including heavy duty truck transmissions (Performance Transportation Services, Inc., et al. v. Eaton Corp., et al.), cable television set top boxes (Marchese v. Cablevision Systems Corp.,et al.) and meningitis vaccines (Castro, et. al. v. Sanofi Pasteur, Inc.)
Mr. Taus also represented plaintiffs and class members in various cases which have been successfully resolved, including Universal Delaware Inc. v. Ceridian Corp., et. al. (settled for $130 million plus injunctive relief), In re Skelaxin Antitrust Litigation (settled for $73 million), In re Metoprolol Succinate Antitrust Litigation (settled for $20 million), In re Wellbutrin XL Antitrust Litigation (partial settlement for $37.5 million); and Rochester Drug Cooperative, Inc. v. Novo Nordisk A/S et al.(settled for $19 million)
Prior to founding Taus, Cebulash & Landau, LLP, Mr. Taus was a partner for 13 years at a New York law firm that specialized in class action litigation. At his prior firm, he acted as Lead Counsel or Co-Lead Counsel for classes of direct purchasers in a number of major, complex antitrust litigations, including In re Cardizem CD Antitrust Litigation (E.D. Mich.) (settled for $110 million); In re Terazosin Hydrochloride Antitrust Litigation (S.D. Fla.) (settled for $75 million); and In re Tricor Antitrust Litigation (D. Del.) (settled for $250 million).
As Lead Counsel for the direct purchaser class in the Tricor case, Mr. Taus successfully negotiated one of the the largest settlements of any direct purchaser class action alleging impeded generic pharmaceutical competition in the Hatch-Waxman antitrust context ($250 million). Prior to settlement, Mr. Taus was responsible for overseeing all material aspects of the litigation on behalf of the direct purchaser class, including the extensive research leading to the initial complaint, analyzing thousands of pages of discovery documents and taking numerous depositions to marshal evidence to support plaintiffs’ theories relating to liability, antitrust impact, causation, monopoly power and class certification, retaining and working closely with numerous experts, and ultimately preparing for and proceeding to trial.
Mr. Taus has successfully played a leading role in various complex consumer class actions, including Cicarell v. Provident Mutual Life Ins. Co.(sales practice litigation settled for $45 million) and Provident Demutualization Litigation (enjoined demutualization that would have harmed policyholders).
Mr. Taus graduated cum laude from the State University of New York at Albany in 1986 with a Bachelor of Science degree in Accounting.Mr. Taus graduated from Brooklyn Law School in 1989, and is admitted to the Bar of the State of New York, as well as the United States District Court for the Southern District of New York and the United States Courts of Appeals for the Second and Eleventh Circuits. He is also a member of the Association of the Bar of the City of New York and the New York State Bar Association.